Study shows early Zytiga use improves prostate cancer survival

CHICAGO (Reuters) - Adding Johnson & Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the risk of death for men newly diagnosed with prostate cancer that had spread to other parts of the body, according to new trial results.